Vanguard Group Inc. Has $13.21 Billion Stake in Gilead Sciences, Inc. $GILD

Vanguard Group Inc. reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 118,983,644 shares of the biopharmaceutical company’s stock after selling 380,582 shares during the quarter. Vanguard Group Inc. owned approximately 9.59% of Gilead Sciences worth $13,207,184,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in GILD. Eagle Rock Investment Company LLC increased its holdings in shares of Gilead Sciences by 2.8% in the third quarter. Eagle Rock Investment Company LLC now owns 9,544 shares of the biopharmaceutical company’s stock valued at $1,059,000 after purchasing an additional 260 shares during the last quarter. Fifth Third Bancorp lifted its stake in shares of Gilead Sciences by 3.9% during the 3rd quarter. Fifth Third Bancorp now owns 393,565 shares of the biopharmaceutical company’s stock worth $43,686,000 after buying an additional 14,642 shares during the last quarter. Pallas Capital Advisors LLC boosted its holdings in shares of Gilead Sciences by 1.6% during the 3rd quarter. Pallas Capital Advisors LLC now owns 8,846 shares of the biopharmaceutical company’s stock worth $982,000 after buying an additional 137 shares during the period. State of New Jersey Common Pension Fund D grew its stake in Gilead Sciences by 3.9% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 435,008 shares of the biopharmaceutical company’s stock valued at $48,286,000 after buying an additional 16,160 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Gilead Sciences by 1.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 420,970 shares of the biopharmaceutical company’s stock valued at $46,728,000 after acquiring an additional 4,834 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on GILD. Rothschild & Co Redburn upped their target price on Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a report on Wednesday. Morgan Stanley lifted their target price on Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Scotiabank upped their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 11th. Finally, Leerink Partners raised their price target on shares of Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Twenty-three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $152.50.

Gilead Sciences Stock Up 2.1%

Shares of NASDAQ GILD opened at $154.98 on Monday. The stock has a market capitalization of $192.28 billion, a P/E ratio of 22.89, a PEG ratio of 2.06 and a beta of 0.36. The stock’s fifty day moving average is $130.27 and its 200 day moving average is $122.38. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the prior year, the business posted $1.90 earnings per share. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is 46.68%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the insider owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. The trade was a 2.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 288,891 shares of company stock valued at $40,303,946 over the last ninety days. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.